Literature DB >> 15147150

Cerebrospinal fluid tau and Abeta42 concentrations in healthy subjects: delineation of reference intervals and their limitations.

Pierre R Burkhard1, Roxane Fournier, Bernadette Mermillod, Karl-Heinz Krause, Constantin Bouras, Irmgard Irminger.   

Abstract

Many limitations and conflicting results have cast serious doubts on the validity of cerebrospinal fluid tau and Abeta42 levels for the biological diagnosis of Alzheimer's disease, particularly extreme variations of the reference limits found by unrelated groups as a consequence of different reference populations used. In this study, we addressed the issue of defining reference limits for cerebrospinal fluid tau and Abeta42 in healthy adult individuals. One hundred and five neurologically intact subjects were enrolled according to strict inclusion criteria, 10 of them with autopsy confirmation of brain integrity. All cerebrospinal fluid samples were similarly and optimally processed as were the dosage methods used and the statistical analyses performed. A robust correlation with age was demonstrated for Abeta42 but not for tau. For tau, we found that an upper cut-off value of 443 ng/l allowed 95% of the subjects to be correctly classified as normal. For Abeta42, a lower cut-off value of 90 ng/l allowed a correct classification of 90% of the subjects. However, a large variance of the reference values, partly explained by the potential contamination of the reference population with presymptomatic dementia patients, may limit the use of reference limits based on living subjects. We propose that the issue of defining reference limits for both cerebrospinal fluid tau and Abeta42 may ultimately be settled by studying large numbers of autopsy-proven neurologically intact individuals only.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15147150     DOI: 10.1515/CCLM.2004.071

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  5 in total

1.  The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease.

Authors:  Lidia Glodzik-Sobanska; Elizabeth Pirraglia; Miroslaw Brys; Susan de Santi; Lisa Mosconi; Kenneth E Rich; Remigiusz Switalski; Leslie Saint Louis; Martin J Sadowski; Frank Martiniuk; Pankaj Mehta; Domenico Pratico; Raymond P Zinkowski; Kaj Blennow; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2007-10-24       Impact factor: 4.673

Review 2.  Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.

Authors:  Catherine Randall; Lisa Mosconi; Mony de Leon; Lidia Glodzik
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01

Review 3.  Methodological Issues in the Clinical Validation of Biomarkers for Alzheimer's Disease: The Paradigmatic Example of CSF.

Authors:  Marco Canevelli; Ilaria Bacigalupo; Giuseppe Gervasi; Eleonora Lacorte; Marco Massari; Flavia Mayer; Nicola Vanacore; Matteo Cesari
Journal:  Front Aging Neurosci       Date:  2019-10-17       Impact factor: 5.750

4.  Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.

Authors:  Kristi Henjum; Ina S Almdahl; Vibeke Årskog; Lennart Minthon; Oskar Hansson; Tormod Fladby; Lars N G Nilsson
Journal:  Alzheimers Res Ther       Date:  2016-04-27       Impact factor: 6.982

5.  Reference Intervals for Plasma Amyloid β in Korean Adults Without Cognitive Impairment.

Authors:  Min Young Kim; Kyu Nam Kim; Hye Min Cho; Duck Joo Lee; Doo Yeoun Cho
Journal:  Ann Lab Med       Date:  2016-11       Impact factor: 3.464

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.